MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is an aggressive cancer with limited treatment options.
• The role of Microtubule-associated serine/threonine kinase-like (MASTL) in HCC pathogenesis is not well understood.

Purpose of the Study:

• To investigate the clinical significance, biological functions, and molecular mechanisms of MASTL in HCC.
• To explore MASTL as a potential prognostic biomarker and therapeutic target for HCC.

Main Methods:

• Bioinformatics analysis of TCGA and ICGC datasets.
• Functional studies involving MASTL knockdown in HCC cells.
• Mechanistic investigations of MASTL's role in mitosis and drug sensitivity.
• Analysis of transcriptional regulation by E2F1.

Main Results:

• MASTL overexpression correlates with advanced HCC stage and poor prognosis.
• MASTL knockdown inhibits HCC cell proliferation, induces mitotic catastrophe, and amplifies DNA damage.
• MASTL influences paclitaxel sensitivity via the ENSA-PP2A-B55α pathway.
• E2F1 directly activates MASTL expression in HCC.

Conclusions:

• MASTL acts as an oncogene in HCC, driven by the E2F1-MASTL-PP2A-B55α axis.
• MASTL is a potential prognostic biomarker and therapeutic target for HCC.
• Combination therapies targeting MASTL warrant further investigation for HCC treatment.